Moffitt logo

Clinical Trials Search

Clinical Trial 21433

Cancer Type: Genitourinary
Study Type: Treatment
NCT#: NCT05369000

Phase: Phase I
Principal Investigator: Zhang, Jingsong

Call 813-745-6100
or 1-800-679-0775 Learn More
Overview

Study Title

A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific γδ-T cell engager, in patients with therapy refractory metastatic castration resistant prostate cancer

Summary

This trial is an open-label Phase 1 and 2a dose escalation trial with an expansion cohort to investigate the safety and tolerability of LAVA-1207 in patients with therapy refractory mCRPC.

Objective

Primary Objectives: Part 1 Dose Escalation To investigate the safety and tolerability of LAVA-1207 in patients with therapy refractory mCRPC. To determine the recommended Phase 2 dose (RP2D) of LAVA-1207 in patients with therapy refractory mCRPC. Part 2 Expansion Cohort To investigate the safety and tolerability of LAVA-1207 at the RP2D in therapy refractory mCRPC patients with measurable disease. Secondary Objectives Part 1 Dose Escalation and Part 2 Expansion Cohort To explore the preliminary antitumor activity of LAVA-1207. To evaluate the pharmacokinetics of LAVA-1207. To evaluate the pharmacodynamics of LAVA-1207. To evaluate the immunogenicity of LAVA-1207.

Treatments

Therapies

Immunotherapy

Medications

LAVA-1207 ()

Inclusion Criteria

INCLUSION CRITERIA:

  • Patient must be 18 years of age inclusive or above, at the time of signing the informed consent.
  • Male patient with mCRPC with measurable or evaluable disease
  • Patient should have failed at least 1 line of taxane-based chemotherapy
  • Patient should have received a 2nd generation or later androgen receptor targeted therapy/ androgen biosynthesis inhibitor
  • Patients with evidence of progressive disease
  • Predicted life-expectancy of ≥ 6 months.
  • ECOG performance status of 0 or 1.
  • Surgically sterile
  • Compliant with an effective contraceptive regimen (i.e. use of male condom with female partner and assuring use of an additional highly effective contraceptive method with a failure rate
  • Capable of giving signed and dated informed consent prior to initiation of any trial-related procedures
  • Other criteria may apply

  • Exclusion Criteria

    EXCLUSION CRITERIA

  • Uncontrolled or severe intercurrent medical condition.
  • Patient has any active-, uncontrolled-, or suspected infection.
  • Known clinically relevant immunodeficiency disorders.
  • Unstable cardiovascular function
  • Previous treatment with an aminobisphosphonate IV (e.g. ibandronate, pamidronate, zoledronate etc) within 4 weeks prior to initial IMP.
  • Known ongoing drug and alcohol abuse in the opinion of the investigator.
  • Additional exclusions may apply

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.